"Develop innovative therapies to improve the quality of life of patients suffering from severe chronic diseases.”
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals
Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated,
multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.
Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.
Ampligen® (poly I:poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching. Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza.
Hemispherx’s platform technology includes
large and small agent components for potential treatment
of various severely debilitating and life threatening
diseases. Hemispherx has an extensive number of patents
comprising its core intellectual property estate and a
fully commercialized product (Alferon N Injection®).
The Company wholly owns and exclusively operates a GMP
certified manufacturing facility in New Brunswick, New
||Hemispherx Biopharma, Inc.
|One Penn Center
1617 JFK Blvd., Suite 500
Philadelphia, PA 19103
NOTE: We will do our best to respond to all inquires. However, we cannot guarantee individual answers.
Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with
the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's
judgment as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.